论文部分内容阅读
耐阿霉素人乳腺癌细胞系MCF7adr具有多药耐受表型,对阿霉素和罗丹明123表现交叉耐受。本研究初步证实中药汤剂R1对MCF7adr细胞有增敏作用。MTT法证实R1可完全逆转MCF7adr细胞对阿霉素的耐受;荧光显微镜和流式细胞技术进一步证实低杀伤或无杀伤浓度R1能增加耐药细胞内阿霉素或罗丹明123的荧光强度。可能为R1使耐药细胞摄取药物量增加或延长药物在细胞内的滞留时间所致。用抗P-糖蛋白的单克隆抗体C219进行免疫细胞化学检测表明:以上作用可能与MCF7adr,细胞表达P-糖蛋白能量下降有密切关系。
The adriamycin-resistant human breast cancer cell line MCF7adr has a multi-drug resistant phenotype and exhibits cross-tolerance to adriamycin and rhodamine 123. This study preliminary confirmed that Chinese medicine decoction R1 has sensitizing effect on MCF7adr cells. MTT assay confirmed that R1 could completely reverse the tolerance of MCF7adr cells to adriamycin; fluorescence microscopy and flow cytometry further confirmed that low or no killing concentration R1 could increase the fluorescence intensity of doxorubicin or rhodamine 123 in drug-resistant cells. It may be caused by an increase in the amount of drug that R1 ingests drug-resistant cells or by prolonging the residence time of the drug in cells. Immunocytochemistry with anti-P-glycoprotein monoclonal antibody C219 showed that the above effects may be closely related to MCF7adr, the decreased expression of P-glycoprotein in cells.